Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Arcturus Therapeutics Holdings Inc. before investing.

In this article, we go over a few key elements for understanding Arcturus Therapeutics Holdings Inc.’s stock price such as:

• Arcturus Therapeutics Holdings Inc.’s current stock price and volume
• Why Arcturus Therapeutics Holdings Inc.’s stock price changed recently
• Upgrades and downgrades for ARCT from analysts
• ARCT’s stock price momentum as measured by its relative strength

About Arcturus Therapeutics Holdings Inc. (ARCT)

Before we jump into Arcturus Therapeutics Holdings Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Want to learn more about Arcturus Therapeutics Holdings Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Arcturus Therapeutics Holdings Inc..

Arcturus Therapeutics Holdings Inc.’s Stock Price as of Market Close

As of January 30, 2026, 4:00 PM, CST, Arcturus Therapeutics Holdings Inc.’s stock price was $7.470.

Arcturus Therapeutics Holdings Inc. is down 1.32% from its previous closing price of $7.570.

During the last market session, Arcturus Therapeutics Holdings Inc.’s stock traded between $7.180 and $7.600. Currently, there are approximately 27.19 million shares outstanding for Arcturus Therapeutics Holdings Inc..

Arcturus Therapeutics Holdings Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Arcturus Therapeutics Holdings Inc. Stock Price History

Arcturus Therapeutics Holdings Inc.’s (ARCT) price is currently up 21.86% so far this month.

During the month of January, Arcturus Therapeutics Holdings Inc.’s stock price has reached a high of $7.930 and a low of $6.015.

Over the last year, Arcturus Therapeutics Holdings Inc. has hit prices as high as $24.170 and as low as $5.850. Year to date, Arcturus Therapeutics Holdings Inc.’s stock is up 21.86%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Arcturus Therapeutics Holdings Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 30, 2026, there were 0 analysts who downgraded Arcturus Therapeutics Holdings Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Arcturus Therapeutics Holdings Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Arcturus Therapeutics Holdings Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Arcturus Therapeutics Holdings Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Arcturus Therapeutics Holdings Inc. (ARCT) by visiting AAII Stock Evaluator.

Relative Price Strength of Arcturus Therapeutics Holdings Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 30, 2026, Arcturus Therapeutics Holdings Inc. has a weighted four-quarter relative price strength of -22.00%, which translates to a Momentum Score of 9 and is considered to be Very Weak.

Want to learn more about how Arcturus Therapeutics Holdings Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Arcturus Therapeutics Holdings Inc. Stock Price: Bottom Line

As of January 30, 2026, Arcturus Therapeutics Holdings Inc.’s stock price is $7.470, which is down 1.32% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Arcturus Therapeutics Holdings Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.